#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	11142	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2144	512.3	0	.	n	.	0	A69G	SNP	69	69	A	318	318	G	628	G,A	602,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	11142	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2144	512.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1433	1433	C	593	C	581	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	20928	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3557	581.1	0	.	n	.	0	T695C	SNP	695	695	T	1036	1036	C	625	C,T,A	597,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	20928	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3557	581.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1678	1678	A	705	A,G	673,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	20928	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3557	581.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2312	2312	C	575	C	561	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	20928	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3557	581.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2386	2386	A	588	A	573	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	20928	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3557	581.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	2938	2938	C	681	C,T	656,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	1380	folP	855	855	100.0	folP.l15.c4.ctg.1	1610	84.6	1	SNP	p	R229S	1	.	.	685	687	AGC	1036	1038	AGC	146;142;141	A;G;C	142;137;138	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3662	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3272	110.5	1	SNP	p	S91F	1	.	.	271	273	TTC	512	514	TTC	121;120;121	T;T;C	117;116;114	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3662	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3272	110.5	1	SNP	p	D95G	1	.	.	283	285	GGC	524	526	GGC	114;116;116	G;G;C	106;108;110	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3662	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3272	110.5	1	SNP	p	G95N	0	.	.	283	285	GGC	524	526	GGC	114;116;116	G;G;C	106;108;110	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	1174	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1273	90.1	1	SNP	p	G45D	0	.	.	133	135	GGC	475	477	GGC	141;143;144	G;G;C,G	140;139;142,1	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	604	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c17.ctg.1	942	63.2	0	.	n	.	0	A197.	DEL	197	197	A	602	602	A	128	A	124	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3488	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3046	113.2	1	SNP	p	D86N	0	.	.	256	258	GAC	599	601	GAC	121;121;124	G;A,C;C	118;110,1;122	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3488	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3046	113.2	1	SNP	p	R87W	0	.	.	259	261	CGT	602	604	CGT	124;122;124	C;G;T	120;117;111	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3488	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3046	113.2	1	SNP	p	R87I	0	.	.	259	261	CGT	602	604	CGT	124;122;124	C;G;T	120;117;111	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3488	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3046	113.2	1	SNP	p	S87R	1	.	.	259	261	CGT	602	604	CGT	124;122;124	C;G;T	120;117;111	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3488	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3046	113.2	1	SNP	p	S88P	0	.	.	262	264	TCC	605	607	TCC	122;123;126	T;C;C	118;118;122	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	2920	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2625	109.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1491	1493	GGC	144;141;140	G;G;C	138;136;134	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	2972	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2449	119.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1275	1277	GCA	157;159;159	G;C;A	152;152;156	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2972	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2449	119.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1278	1280	ATC	161;161;162	A;T;C	158;158;158	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2972	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2449	119.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1290	1292	GTG	165;164;163	G;T;G	160;159;160	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2972	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2449	119.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1290	1292	GTG	165;164;163	G;T;G	160;159;160	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2972	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2449	119.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1794	1796	ACC	153;152;153	A;C;C	143;142;145	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2972	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2449	119.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1848	1850	GCG	128;127;126	G;C,T;G	115;106,1;114	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2972	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2449	119.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1848	1850	GCG	128;127;126	G;C,T;G	115;106,1;114	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2972	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2449	119.2	1	SNP	p	G543S	1	.	.	1627	1629	AGC	1971	1973	AGC	114;113;112	A,C;G;C	109,1;109;107	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2972	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2449	119.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1980	1982	GGC	113;112;111	G;G;C	109;109;107	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2972	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2449	119.2	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1998	2000	CCG	84;89;89	C,G;C,A,T,G;G,C	69,3;73,1,1,1;76,1	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4258	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3117	134.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1633	1635	CCG	156;155;153	C,G;C;G	147,1;149;145	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1634	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1746	91.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	462	462	C	105	C	100	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2238	porB1b	1047	1047	99.24	porB1b.l6.c30.ctg.1	1619	134.9	0	.	p	.	0	N38E	NONSYN	112	114	AAT	395	397	GAA	189;186;183	G;A;A	180;180;178	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2238	porB1b	1047	1047	99.24	porB1b.l6.c30.ctg.1	1619	134.9	0	.	p	.	0	N134D	NONSYN	400	402	AAT	683	685	GAT	184;185;185	G;A;T	178;180;179	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2238	porB1b	1047	1047	99.24	porB1b.l6.c30.ctg.1	1619	134.9	0	.	p	.	0	P175S	NONSYN	523	525	CCA	806	808	TCA	163;165;165	T;C;A	158;160;161	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2238	porB1b	1047	1047	99.24	porB1b.l6.c30.ctg.1	1619	134.9	0	.	p	.	0	A218V	NONSYN	652	654	GCC	935	937	GTC	184;184;183	G;T,G;C	179;173,1;178	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2238	porB1b	1047	1047	99.24	porB1b.l6.c30.ctg.1	1619	134.9	0	.	p	.	0	F222S	NONSYN	664	666	TTT	947	949	TCT	173;176;179	T,G;C;T	167,1;174;177	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2238	porB1b	1047	1047	99.24	porB1b.l6.c30.ctg.1	1619	134.9	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1265	1267	GCA	180;179;180	G;C;A	169;169;171	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2238	porB1b	1047	1047	99.24	porB1b.l6.c30.ctg.1	1619	134.9	1	SNP	p	G120K	1	.	.	358	360	AAG	641	643	AAG	172;173;174	A;A;G	167;167;165	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2238	porB1b	1047	1047	99.24	porB1b.l6.c30.ctg.1	1619	134.9	1	SNP	p	D121N	0	.	.	361	363	GAC	644	646	GAC	173;175;177	G;A;C	166;164;170	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2238	porB1b	1047	1047	99.24	porB1b.l6.c30.ctg.1	1619	134.9	1	SNP	p	A121D	1	.	.	361	363	GAC	644	646	GAC	173;175;177	G;A;C	166;164;170	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	7824	rpoB	4179	4179	99.98	rpoB.l6.c30.ctg.1	5000	154.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	966	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1066	89.5	1	SNP	p	V57M	1	.	.	169	171	ATG	570	572	ATG	194;194;195	A;T;G	186;182;185	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
